Common Stock, $0.0001 par value per share
- Symbol
- PCSA
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 8.01, 9.01 · 8-K
Processa Pharmaceuticals, Inc.
PCSANASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events On October 27, 2026, Justin Yorke resigned as chair of the board of directors (the “Board”) of Processa Pharmaceuticals, Inc. (the “Company”), and on October 28, 2026, the Board appointed Dr. Sheila Gujrathi as the non-employee executive chair (the “Executive Chair”) of the Board, effective immediately. Mr. Yorke will continue as a member of the Board.…
Press release in this filing
Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics →Company context
We are a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (“NGC”) small molecules, two of which are in, or have completed, Phase 2 trials, and one is in pre-clinical development.
Current securities
Historical securities (1)
Registered securities in this filing
Processa Pharmaceuticals, Inc. · 8-K · Filed 2026-10-29
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events
On October 27, 2026, Justin Yorke resigned as chair of the board of directors (the “Board”) of Processa Pharmaceuticals, Inc. (the “Company”), and on October 28, 2026,
the Board appointed Dr. Sheila Gujrathi as the non-employee executive chair (the “Executive Chair”) of the Board, effective immediately. Mr. Yorke will continue as a member of the Board.
On October 29, 2026, the Company issued a press release announcing Dr. Gujrathi’s appointment as Executive Chair, among other corporate updates. A copy of the press
release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosis Company expands pipeline through research collaboration of a novel, oral macrocyclic peptide-based neonatal Fc receptor antagonist program from Generian Pharmaceuticals Sheila Gujrathi, M.D., appointed Executive Chair of Processa Board of Directors Cash runway expected to fund operations into the second half of 2029 VERO BEACH, FL, October 29, 2026 - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company developing VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced continued execution following its acquisition of Vidya Therapeutics (“Vidya”). Progress includes U.S. Food and Drug Administration (FDA) clearance of the investigational new drug (IND) application for a Phase 2 study of VT-7208 in chronic spontaneous urticaria (CSU), expansion of the pipeline through a re…
Open exhibit ↗